(Q33411581)

English

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

object named as

David C Smith

15

0 references

Stephanie Daignault

2

object named as

Stephanie Daignault

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Petros D Grivas

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott T Tagawa

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David M Nanus

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Walter M Stadler

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert Dreicer

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Manish Kohli

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Daniel P Petrylak

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David J Vaughn

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kathryn A Bylow

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Steven G Wong

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joseph L Sottnik

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Evan T Keller

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mahmoud Al-Hawary

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maha Hussain

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

18 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

120

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

692-701

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

VEGF receptor expression and signaling in human bladder tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Phase II study of sunitinib in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

21 January 2018

Quantification of angiongenesis as an independent predictor of prognosis in invasive bladder carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28477

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28477

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33411581&oldid=1563663254"